- /
- Supported exchanges
- / US
- / PACB.NASDAQ
Pacific Biosciences of California (PACB NASDAQ) stock market data APIs
Pacific Biosciences of California Financial Data Overview
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pacific Biosciences of California (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pacific Biosciences of California data using free add-ons & libraries
Get Pacific Biosciences of California Fundamental Data
Pacific Biosciences of California Fundamental data includes:
- Net Revenue: 159 M
- EBITDA: 199 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Pacific Biosciences of California Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pacific Biosciences of California News
New
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Pacific Biosciences of California (PACB). Shares have added about 11.6% in that time frame, outperforming the S&P 500. But investors have to be ...
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
10x Genomics, Inc. TXG has surged 84% in the past three months, putting pressure on its fundamentals to keep pace with the stock. Consumables growth, Atera demand and a higher 2026 outlook provide sup...
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
Pacific Biosciences of California, Inc. PACB, or PacBio, cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition offset improving clinical activity. The revision raise...
3 Reasons to Sell PACB and 1 Stock to Buy Instead
3 Reasons to Sell PACB and 1 Stock to Buy Instead Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was par...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.